Khartis emerges from stealth with $95M to challenge Tepezza: Venture Report

A San Diego start-up incubated by Foresite has emerged from stealth with $95 million in total funding to date and an oral alternative to blockbuster thyroid eye disease drug Tepezza.

Khartis Therapeutics Inc. unveiled itself early Thursday, disclosing a new $50 million series B that followed $45 million in prior funding. Co-founded by three former executives at Xinthera Inc. who reunited after Gilead Sciences Inc. (NASDAQ:GILD) acquired that company in 2023 for $200 million up front, Khartis spent its infancy in the Foresite Labs program operated by series A investor Foresite Capital...